Company / R&D Expense
CRESCENT BIOPHARMA, INC. R&D Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$138.1M
FY2025
5-year range
$9.4M / $138.1M
FY2021-FY2025
Trend
+451.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense changed +451% YoY in FY2025, a notable deviation from the 4-year average annual change of +143%.
Based on SEC 10-K filings.
$138M in FY2025 with a 10-year CAGR of +28.0%.
Improved from $20M to $138M over the past 9 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +28.0%
Key checks
Key Insights
- CRESCENT BIOPHARMA, INC.'s r&d expense has grown for 4 consecutive years.
- In FY2025, r&d expense increased 451.2% year-over-year.
- Lowest r&d expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $138.1M | +451.2% |
| FY2017 | $25.1M | +28.0% |
| FY2016 | $19.6M | +67.3% |
| FY2015 | $11.7M | +24.0% |
| FY2014 | $9.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026